Home / Markets / Industries / Health Care
Monday, October 06, 2008
CryoCath Announces Filing and Mailing of Directors' Circular Unanimously Recommending Acceptance of Offer from Medtronic
Comtex
MONTREAL, Oct. 6, 2008 (Canada NewsWire via COMTEX) ----
<< www.cryocath.com Toronto Stock Exchange Symbol: CYT >>
CryoCath(R) Technologies Inc. ("CryoCath" or the "Company") (TSX: CYT), today announced the filing and mailing of the Directors' Circular with respect to the previously announced offer from Medtronic, Inc. ("Medtronic") (NYSE: MDT), through a wholly owned subsidiary, to acquire all of the outstanding common shares of the Company. The Directors' Circular is being mailed together with the take-over bid circular of Medtronic.
The CryoCath board of directors has unanimously recommended that CryoCath shareholders accept the offer. The Directors' Circular provides details concerning the board of directors' recommendation that the Company's shareholders tender their common shares into the offer. The Directors' Circular has been filed in Canada on SEDAR at www.sedar.com and will also be available on CryoCath's website at www.cryocath.com.
About CryoCath
CryoCath - www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With annual revenue of approximately $40 million Cdn, its products are routinely used in more than 500 centers around the world. The Company's flagship product, Arctic Front, is a minimally invasive cryo-balloon catheter designed specifically to treat Atrial Fibrillation, an emerging $2 billion market opportunity. Marketed in Europe and the subject of a pivotal study in the United States, Arctic Front has been used to treat approximately 3,100 patients.
This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
%SEDAR: 00015053EF
SOURCE: CryoCath Technologies Inc.
visit our website at www.cryocath.com, or contact: Ross Marshall, Investor Relations, Phone: (416) 815-0700 ext. 238, Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com
Copyright (C) 2008 CNW Group. All rights reserved. ********************************************************************** As of Thursday, 10-02-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a DOWNTREND on 09-17-2008 for MDT @ $52.47. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.
FOX Translator
No data currently available.
No data currently available.
Some mutual funds want you to pay for the privilege of them (or your investment adviser) taking your money to invest. It's called a load, and it works like a cover charge to get into a nightclub. Luckily, there are such things as no-load funds. As the name implies, shares of these funds are sold without a fee paid to a broker or investment advisor.
The entire amount you invest in no-load funds goes to work for your returns. On the other hand, with load funds, right off the bat you're charged commission (not to mention other fees incurred over the life of the investment). Let's say, for example, you invest $25,000 into a load fund that charges a 5% commission. This costs you $1,250 off the top, bringing your actual investment down to only $23,750.
The often-cited horse race analogy argues against investing in load funds. Here's the logic behind it: Would you place a bet on a horse that had to start a race 200 yards behind the others? Well, maybe you would if you got a tip from a sketchy, trench coat-clad man in a dark alley. However, under most circumstances, it's not smart to put your money on that handicapped horse.
But some argue that at times that man in the trench coat (aka your broker) knows more about the horses than you do, and has a better shot at picking a winner. Also, sometimes these fees are unavoidable because some funds are available only through investment advisers.
Cost-benefit analysis can help determine when a load fund is worth it (in other words, when it will score you a load) and when it is better to "do it yourself" and avoid the fees. Load-fund fees range depending on share class and can cover a variety of costs, such as paper work and fund management.
